OncoCyte (NYSEAMERICAN:OCX) Stock Price Up 6%

OncoCyte Corp (NYSEAMERICAN:OCX)’s stock price rose 6% during trading on Wednesday . The company traded as high as $1.79 and last traded at $1.76, approximately 254,063 shares traded hands during trading. A decline of 61% from the average daily volume of 654,999 shares. The stock had previously closed at $1.66.

OCX has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of OncoCyte from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. Chardan Capital set a $8.00 price target on shares of OncoCyte and gave the company a “buy” rating in a report on Friday, May 17th. Finally, Benchmark reiterated a “buy” rating on shares of OncoCyte in a report on Wednesday, July 3rd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $6.10.

OncoCyte (NYSEAMERICAN:OCX) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.10).



In related news, major shareholder Broadwood Partners, L.P. acquired 1,000,000 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The shares were bought at an average price of $2.00 per share, for a total transaction of $2,000,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Biotime Inc sold 2,250,000 shares of the stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $2.00, for a total transaction of $4,500,000.00. The disclosure for this sale can be found here.

A number of institutional investors have recently modified their holdings of OCX. Spark Investment Management LLC bought a new position in OncoCyte during the first quarter valued at approximately $159,000. Commonwealth Equity Services LLC lifted its position in OncoCyte by 17.3% during the second quarter. Commonwealth Equity Services LLC now owns 35,206 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 5,200 shares during the period. Wells Fargo & Company MN lifted its position in OncoCyte by 77,522.4% during the second quarter. Wells Fargo & Company MN now owns 38,035 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 37,986 shares during the period. Acadian Asset Management LLC bought a new position in OncoCyte during the second quarter valued at approximately $30,000. Finally, Charles Schwab Investment Management Inc. lifted its position in OncoCyte by 337.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 57,938 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 44,686 shares during the period.

OncoCyte Company Profile (NYSEAMERICAN:OCX)

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Recommended Story: Limitations of analyzing profit margin

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.